Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant
Sumitomo Dainippon Pharma is set to fork over US$3 billion upfront to gain ownership stakes in five businesses under the aegis of Roivant Sciences, with President and CEO Hiroshi Nomura confident that their still-preliminary deal would help his company skirt…
To read the full story
Related Article
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
- Roivant Wants to Validate Its Biz Model with Commercial Success of Sumitomo Dainippon Alliance: CEO
November 5, 2019
- Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
November 1, 2019
- To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
BUSINESS
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
- Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
March 17, 2026
- Olumiant Gains Oral Suspension Formulation in Japan
March 17, 2026
- BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…